Clinical relevance of TDM of SSRIs [4]

Therapeutic Drug Monitoring

Volumn 28, Issue 5, 2006, Pages 716-717

  Schwarz, Markus J ^a   Hiemke, Christoph ^b   Baumann, Pierre ^c  

^a UNIVERSITY OF MUNICH   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c Unité de Biochimie et Psychopharmacologie Clinique   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CITALOPRAM; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; NORSERTRALINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

DRUG BLOOD LEVEL; DRUG MILK LEVEL; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; LETTER; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; TREATMENT REFUSAL;

CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; DRUG MONITORING; HUMANS; PATIENT COMPLIANCE; PHARMACOGENETICS; SEROTONIN UPTAKE INHIBITORS;

EID: 33749855491     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000245378.87563.72     Document Type: Letter

References (19)

1. Franssen EJ, Meijs V, Ettaher F, et al. Citalopram serum and milk levels in mother and infant during lactation. Ther Drug Monit. 2006;28:2-4.
2. Knoppert DC, Nimkar R, Principi T, et al. Paroxetine toxicity in a newborn after in utero exposure: clinical symptoms correlate with serum levels. Ther Drug Monit. 2006;28:5-7.
3. Koren G. A new indication for therapeutic drug monitoring in the neonate. Ther Drug Monit. 2006;28:1.
4. Bareggi SR, Bianchi L, Cavallaro R, et al. Citalopram concentrations and response in obsessive-compulsive disorder. Preliminary results. CNS Drugs. 2004;18:329-35.
5. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37:243-65.
6. Baumann P, Hiemke C, Ulrich S, et al. Therapeutic monitoring of psychotropic drugs: an outline of the AGNP-TDM expert group consensus guideline. Ther Drug Monit. 2004;26:167-70.
7. Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand. 2002;105:164-72.
8. Starace F, Ammassari A, Trotta MP, et al. Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31:S136-9.
9. Gilbert JR, Evans CE, Haynes RB, et al. Predicting compliance with a regimen of digoxin therapy in family practice. Can Med Assoc J. 1980;123:119-22.
10. Reis M, Aberg-Wistedt A, Agren H, et al. Compliance with SSRI medication during 6 months of treatment for major depression: an evaluation by determination of repeated serum drug concentrations. J Affect Disord. 2004;82:443-6.
11. Meijer WE, Bouvy ML, Heerdink ER, et al. Spontaneous lapses in dosing during chronic treatment with selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;179:519-22.
12. Michelson D, Fava M, Amsterdam J, et al. Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. Br J Psychiatry. 2000;176:363-8.
13. Hiemke C, Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000;85:11-28.
14. Ng CH, Schweitzer I, Norman T, et al. The emerging role of pharmacogenetics: implications for clinical psychiatry. Aust NZ J Psychiatry. 2004;38:483-9.
15. Kirchheiner J, Fuhr U, Brockmoller J. Pharmacogenetics-based therapeutic recommendations-ready for clinical practice? Nat Rev Drug Discov. 2005;4:639-47.
16. van der Weide J, van Baalen-Benedek EH, Kootstra-Ros JE. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype. Ther Drug Monit. 2005;27:478-83.
17. Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab. 2002;3:13-37.
18. Ciusani E, Zullino DF, Eap CB, et al. Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects. J Psychopharmacol. 2004;18:559-66.
19. Lundmark J, Bengtsson F, Nordin C, et al. Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatr Scand. 2000;101:354-9.